Rockville, Maryland-based OncoImmune closed on a Series B round worth $56 million, co-led by HM Capital and a blue-chip investor.
Veru Inc. is developing a dual anti-inflammatory/antiviral medication to combat severe Covid-19 infections.
Gilead Sciences started an early-stage study of the company’s antiviral COVID-19 treatment remdesivir that can be inhaled, for use outside of hospitals.
British medical journal The Lancet has concerns about data behind an influential article that found hydroxychloroquine increased the risk of death in COVID-19 patients, a conclusion that undercut scientific interest in the medicine championed by U.S. President Donald Trump.
U.S. researchers, following the lead of scientists in other countries, launched studies to see whether widely available, low-cost generic drugs can be used to help treat the illness caused by the new coronavirus.
A clinical trial fell short of producing statistical evidence that Novartis’ anti-inflammatory drug Cosentyx can beat the world’s best-selling medicine Humira in treating a type of arthritis.
In 2015, Pfizer researchers were analyzing hundreds of thousands of insurance claims and noted that patients receiving the company’s anti-inflammatory Enbrel appeared to have a reduced risk of Alzheimer’s disease – by a startling 64 percent.
On Sept. 11, 2017, Regeneron Pharmaceuticals and Sanofi announced positive data for its Phase III LIBERTY ASTHMA QUEST trial of Dupixent (dupilumab) in asthma. Investors and analysts do not seem to agree on whether dupilumab is on its way to being one of the biggest blockbuster drugs in the last two years, or if it’s the most overhyped drug on the market.
An anti-inflammatory drug developed for cardiac patients has an exciting, yet unintended side effect – possible prevention of lung cancer.